Travere Therapeutics (NASDAQ:TVTX) Shares Down 4.3% - What's Next?

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report)'s share price dropped 4.3% during trading on Wednesday . The company traded as low as $20.50 and last traded at $20.20. Approximately 232,515 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 1,234,086 shares. The stock had previously closed at $21.10.

Analysts Set New Price Targets

Several research firms recently commented on TVTX. Barclays upped their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an "overweight" rating in a research report on Friday, November 1st. Scotiabank raised their price target on Travere Therapeutics from $23.00 to $27.00 and gave the stock a "sector outperform" rating in a report on Friday, November 1st. Bank of America boosted their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, October 9th. Piper Sandler raised their price objective on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday, November 14th. Finally, Wedbush raised their price objective on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an "outperform" rating in a research report on Wednesday, October 9th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $24.00.

Travere Therapeutics Stock Down 4.2 %

The firm's 50 day moving average is $18.46 and its 200-day moving average is $15.10. The firm has a market cap of $1.58 billion, a PE ratio of -4.45 and a beta of 0.70. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.01. The company had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The business's revenue for the quarter was up 69.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.17) EPS. As a group, equities research analysts expect that Travere Therapeutics, Inc. will post -3.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Peter Heerma sold 1,584 shares of the company's stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total value of $30,000.96. Following the completion of the sale, the insider now owns 106,374 shares of the company's stock, valued at $2,014,723.56. This represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Sandra Calvin sold 15,000 shares of the company's stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $17.22, for a total value of $258,300.00. Following the completion of the sale, the chief accounting officer now directly owns 54,927 shares of the company's stock, valued at $945,842.94. The trade was a 21.45 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 62,143 shares of company stock valued at $1,167,512. 3.75% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Creative Planning lifted its holdings in Travere Therapeutics by 4.3% during the 3rd quarter. Creative Planning now owns 23,938 shares of the company's stock worth $335,000 after buying an additional 995 shares during the last quarter. R Squared Ltd bought a new stake in shares of Travere Therapeutics in the 4th quarter worth approximately $53,000. CWM LLC lifted its holdings in shares of Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company's stock worth $70,000 after purchasing an additional 3,065 shares during the last quarter. Diversified Trust Co boosted its position in Travere Therapeutics by 27.5% during the 4th quarter. Diversified Trust Co now owns 14,701 shares of the company's stock valued at $256,000 after purchasing an additional 3,169 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Travere Therapeutics by 20.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,969 shares of the company's stock worth $279,000 after buying an additional 3,458 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.